

# Neena Kapoor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4001214/publications.pdf>

Version: 2024-02-01

44  
papers

2,254  
citations

361413

20  
h-index

265206

42  
g-index

47  
all docs

47  
docs citations

47  
times ranked

3205  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 729.  | 7.4  | 586       |
| 2  | Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. <i>Blood</i> , 2017, 130, 2718-2727.  | 1.4  | 212       |
| 3  | Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 45-63.   | 27.6 | 178       |
| 4  | Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017. <i>Pediatrics</i> , 2019, 143, .   | 2.1  | 148       |
| 5  | SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood</i> , 2018, 132, 1737-1749.  | 1.4  | 128       |
| 6  | Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1282-1292.  | 2.9  | 107       |
| 7  | Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2010, 116, 829-829.                                   | 1.4  | 98        |
| 8  | Hematopoietic stem cell transplantation for infantile osteopetrosis. <i>Blood</i> , 2015, 126, 270-276.  | 1.4  | 89        |
| 9  | Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. <i>Blood</i> , 2020, 135, 2094-2105.   | 1.4  | 87        |
| 10 | The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 405-407.  | 2.9  | 64        |
| 11 | Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. <i>Frontiers in Immunology</i> , 2020, 11, 239.   | 4.8  | 57        |
| 12 | Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1437-1446. | 2.0  | 45        |
| 13 | Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. <i>Journal of Clinical Immunology</i> , 2019, 39, 653-667.  | 3.8  | 41        |
| 14 | Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017, 102, 1291-1298.  | 3.5  | 38        |
| 15 | B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. <i>Blood</i> , 2018, 131, 2967-2977.  | 1.4  | 37        |
| 16 | Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.  | 3.8  | 36        |
| 17 | International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 410-421.e7.   | 2.9  | 34        |
| 18 | Gene Therapy for Adenosine Deaminase Deficiency. <i>Annual Review of Medicine</i> , 2000, 51, 33-47.   | 12.2 | 32        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.   | 27.6 | 31        |
| 20 | Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene. <i>Journal of Clinical Immunology</i> , 2015, 35, 15-21.   | 3.8  | 25        |
| 21 | Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50 Years or Older with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 488-495.  | 2.0  | 21        |
| 22 | Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656. | 2.0  | 18        |
| 23 | Human Lymphoid Development in the Absence of Common $\gamma$ -Chain Receptor Signaling. <i>Journal of Immunology</i> , 2014, 192, 5050-5058.   | 0.8  | 15        |
| 24 | Immunologic Resolution of Human Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1508-1515.   | 2.0  | 15        |
| 25 | Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2020, 4, 2158-2162.   | 5.2  | 15        |
| 26 | Bronchoscopic instillation of surfactant in acute respiratory distress syndrome. <i>Pediatric Pulmonology</i> , 2001, 31, 317-320.   | 2.0  | 14        |
| 27 | Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 2004-2007.  | 2.9  | 14        |
| 28 | Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy. <i>Blood Advances</i> , 2022, 6, 1512-1524.  | 5.2  | 11        |
| 29 | A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 440-444.   | 2.0  | 10        |
| 30 | Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. <i>American Journal of Hematology</i> , 2015, 90, 1021-1026.   | 4.1  | 9         |
| 31 | Infusion of Alloantigenized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2018, 24, 4098-4109.   | 7.0  | 9         |
| 32 | Administration of BPX-501 Cells Following $\alpha$ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. <i>Blood</i> , 2018, 132, 307-307.   | 1.4  | 8         |
| 33 | Graft versus tumor effect in the brain of a child with recurrent metastatic medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1667-1669.  | 1.5  | 5         |
| 34 | Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD). <i>Blood</i> , 2018, 132, 2207-2207.  | 1.4  | 4         |
| 35 | Hematopoietic stem cell transplantation for severe combined immune deficiency. <i>Current Allergy and Asthma Reports</i> , 2001, 1, 416-420.   | 5.3  | 3         |
| 36 | Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9). <i>Blood</i> , 2016, 128, 72-72.   | 1.4  | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Graft-versus-host disease and immunosuppression. Immunologic Research, 2008, 41, 34-44.   | 2.9 | 1         |
| 38 | Improved Outcomes After Reduced Intensity Conditioning Matched Unrelated Donor Hematopoietic Stem Cell Transplantation In Children With Chronic Granulomatous Disease. Blood, 2013, 122, 2272-2272. | 1.4 | 1         |
| 39 | The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation. Blood, 2012, 120, 762-762.  | 1.4 | 1         |
| 40 | Hematopoietic stem cell transplantation: current status of old issues. Journal of Clinical Immunology, 2001, 21, 377-380.   | 3.8 | 0         |
| 41 | Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia. Blood, 2015, 126, 561-562.  | 1.4 | 0         |
| 42 | Campath 1H Versus ATG for the Prophylaxis of Graft Versus Host Disease Does Not Increase the Risk of Relapse or Infections.. Blood, 2006, 108, 2888-2888.   | 1.4 | 0         |
| 43 | Chronic Graft-Versus-Host Disease and Systemic Sclerosis: The Same Pathophysiology?.. Blood, 2011, 118, 4076-4076.  | 1.4 | 0         |
| 44 | Impact of Thymic Function On Chronic Graft-Versus-Host Disease (cGVHD).. Blood, 2012, 120, 3052-3052.   | 1.4 | 0         |